Healthcare
MannKind Corporation(MNKD)
Live Price
Offline$3.94
+0.51% today
1Y Change
+0.52%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $880.00M
- Revenue Growth
- +22.2%
- EPS Growth
- -80.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MannKind Corporation (MNKD) is a Healthcare stock with a market cap of $880.00M and listed on NASDAQ. The stock last traded around $3.94 and up 0.5% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +22.2%, EPS growth of -80.0%, a dividend yield of 0.0%. What stands out right now is revenue +22.2%, EPS -80.0%, free cash flow -58.3% with operating margin 11.1% and ROIC 5.8%. Valuation already assumes a fairly strong business story at P/E 148.0 and price/sales 2.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines MNKD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+22.2% vs +7.6% peer median
Operating Margin
Below sector median
+11.1% vs +19.4% peer median
P/E
Above sector median
148.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +22.2% and EPS is at -80.0%, with operating margin around 11.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -4.0% | +2.8% | +13.7% |
2026 Feb 26, 2026 | -400.0% | +1.2% | -12.7% | -29.0% |
2025 Nov 5, 2025 | +200.0% | -5.9% | -13.4% | -5.8% |
Benchmark Edge
MNKD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MNKD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MNKD Max Drawdown
-63.29%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MNKD and SPY.
Company Overview
MannKind Corporation
NASDAQ Global Market
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
- Leadership
- Michael E. Castagna
- IPO Date
- Jul 28, 2004
- Employees
- 403
- Street Address
- 30930 Russell Ranch Road
- Mailing
- Danbury, CA, 91362
- Region
- Danbury, CA, US
- Reporting Currency
- USD
- Investor Line
- 818 661 5000
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 148.0
- EV/EBITDA
- 24.5
- Price/Sales
- 2.5
- Price/Book
- โ
Growth
- Revenue
- +22.2%
- EPS
- -80.0%
- Free Cash Flow
- -58.3%
Profitability
- Gross Margin
- 76.4%
- Operating Margin
- 11.1%
- Net Margin
- 1.7%
- ROE
- -11.2%
- ROIC
- 5.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.70
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.